Monte Rosa Therapeutics appoints Eric A. Hughes, M.D., Ph.D. to Board of Directors

Monte Rosa Therapeutics, Inc.

Dr. Hughes is Executive VP, Global R&D and Chief Medical Officer at Teva Pharmaceuticals; previously at Vertex, Novartis, BMS.
Granted option to purchase 44,200 shares vesting monthly over 36 months; annual director fee of $40,000.
Also eligible for annual stock option grants of 22,100 shares after each annual meeting starting 2025.
Board determined Dr. Hughes is independent under Nasdaq standards; serves as Class III director until 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.